Hypercholesterolemia and hypertriglyceridemia—greatest cardiac risk in subjects with high apoB/apoA-I levels

International Congress Series

Volumn 1262, Issue C, 2004, Pages 203-206

  Walldius, Göran ^a,b   Aastveit, Are ^c   Jungner, Ingmar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Cholesterol; Myocardial infarction; Triglycerides

Indexed keywords

EID: 84973332839     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2003.12.033     Document Type: Article

References (5)

1. G. Walldius I. Jungner I. Holme A.H. Aastveit W. Kolar E. Steiner High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
2. A.D. Sniderman C.D. Furberg A. Keech J.E. Roeters van Lennep J. Frohlich I. Jungner G. Walldius Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 2003 777 780
3. I. Jungner S.M. Marcovina G. Walldius I. Holme W. Kolar E. Steiner Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization—International Federation of Clinical Chemistry First International Reference Materials Clin. Chem. 44 1998 1641 1649
4. International Atherosclerosis Society, Harmonized clinical guidelines on prevention of atherosclerotic vascular disease, Executive Summary, 2003, 1–23, http://www.info@athero.org .
5. S.M. Grundy Low-density lipoprotein, non-high density lipoprotein, and apolipoprotein B as targets of lipid lowering therapy Circulation 106 2002 2526 2529